Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Every time they file its that sentence "we intend to become current" that keeps me smiling. This is worth far more than .05/ share .Mulye to the rescue !!!
Yep, gettin’ there. Slowly…
10K was ammended
https://genebiotherapeutics.com/investors/
All of the rest of filings do not have much to out into quartely and yearly because very little has taken place as far as investors know about CRXM?? So, besides money part, should only take a couple of months to be trading again. But, if no money, then might be 2023??
CRXM, someday in 2022 we could trade again?
In only my opinion
so now we have all of 2021 filings to get current probably first Q of 2022 by the time its all done
I was confident that JJ and Bentley were not BS-ing. Never underestimate the value of insider info. RAM came thru as they promised JJ!
Ks take longer to file, it's just the plain and simple truth of it. You have auditors asking you for 10x the amount of data. Plus the level of assurance (aka the risk and liability for the audit firm goes up). I'd assume the Qs will be a lot quicker then we'll hit a bit of wall again for the 2021 K. Just a best guess
-some random cpa
I would expect 2021 Fins to be much easier to assemble as the historical hard part has been done.
From an accounting perspective they have started on this path well over a year ago, so they should've been doing better bookkeeping since decision was made to be fully reporting.
Now, paying for the filing is a different story. We shall see...
JJ24.....Nostrum Has Annual Sales Over $200 Million A Year So Funding CRXM Should Be No Problem.....I Agree And Look Forward To Good News Moving Forward!
You would think the $3.8 million ,the funding they need to start phase 3 would be a small risk for some to have a chance at a drug that could generate Billions of dollars! Lets hope they get the filings they need to get current out a lot faster! Good luck to all longs!
the legal section of latest SEC filing shows that they need to raise money to continue to be a going concern as is evidenced by the rent owed along with a 307,000 unpaid note.. Nostrum is in the drivers seat and it appears that all statements continue to point the way to continued filings and deferred amts owed to later dates. What the company shares will look like remains to be seen .Maybe a private financing with Nostrum surrendering shares to a JV might be the way to go....time will tell.
That would be nice. I scanned through the 10-k and did not see anything that would lift my hopes here but the fact they made the effort to file it is promising. They are still a very long ways from becoming current, but they are still alive...a good thing.
I believe its about buying time to secure a JV deal ....a least its moving forward albeit at a snails pace....a partner would speed this up rapidly and suffer less dilution
So 4 more Qs and 1 K for 2021 required, maybe see those by 2024.
docj.....Nostrum Has Invested Several $Million Dollars Along With Their Time And Effort For A Reason....Nostrum Also Has Their Staff Involved.....CRXM Will Be On Track And Move Forward At This Point IMHO
Maybe this allows for speeding up the process. This one took 5 months. At this rate they will never get current and trade.
They have to come up with funds for manufacturing.
docj.....Thanks real progress.....Look forward to more good news and seeing the stock trading on the OTCQB.....Shareholders really appreciate the heads up!
I don't get you. You are unhappy when someone disagrees with you, and you're unhappy when they agree. No winning with you.
Regardless of the position size VERY Optimistic about this. With all the knowledge you guys have and the RAM connection I'm excited for the future! Nothing wrong with excitement. Watch this open 50c+. You and Bentley got this!
Ram never promised me anything. Stop referring to me in your posts . Why you so active on a board that you have such a small position in? Makes no sense .
But RAM promised you and Zaporozhets "timely fashion" reporting. They changed their mind? What a sad day
Means I’m close to a year of holding this, to bad it means nothing atm
What’s up Doc? Just trying my best to stay positive here. Lots of money tied up here . It’s been almost a year since this PR:
If we don’t hear something soon, I might volunteer myself for this trial . Lol!
SAN DIEGO, CA – April 26, 2021 - Gene Biotherapeutics Inc. (OTC: CRXM) announced today that it has entered into an agreement with FUJIFILM Diosynth Biotechnologies (“FDB”) to manufacture the Generx [Ad5FGF-4] angiogenic gene therapy product candidate for Phase 3 clinical evaluation for the treatment of refractory angina due to late-stage coronary artery disease. Manufacturing operations will be conducted at FDB’s facilities in College Station, TX where FDB will perform technology transfer and process development activities for Phase 3 clinical and commercial-scale GMP manufacturing of Generx.
now that's funny !!!
Again I'll reiterate,,, No one knows anything here ..they're may be some cheer leaders in the company (no names mentioned) who talk to a few but they have so far delivered nothing and we've heard nada from the Chiefs at Nostrum, who are clearly driving the bus .There are no golden nuggets to add....its wait and see which way the coin flips period. Don't care who posts their 50 million in real estate or the shoe shine guy with 5 shares ....you all know nothing.
Right On! Good to Hear!
Bentley and JJ have insider info knowledge. They have assured us all this will be current "in a timely fashion." Let's take their trustworthy word and be patient. Why would they lie? They have direct contact with RAM and were assured that its all peachy.
This is DEFINITELY coming back!
Looks like they played everybody. No trading symbol, no updates??
Are we missing something or are you insider?? Don't be silly son. OTC shenanigans. Lol!
Got me for $8,000 loss.
CRXM??
who played who ??....Nostrum has 2 mill of zero worth you speak silly ..I think they are waiting till the opportunity is right or will accept zero...must wait an see.
They played everybody and now shareholders have worthless shares. Maybe someone will buy this shell??
CRXM????
Afraid your assumption may be correct. If there was any glimmer of hope, I am guessing we would have heard by now. Was hoping they would have completed Phase 3 this year but am doubting they will even start it this year. So much for Fast Track designation! Lol.
Yes its into late March now ...one might assume they haven't been able to raise up any interest in CRXM tech....then again Mulye isn't one to waste several million dollars and biotech hasn't been too stellar either the last 12 months....we will just have to wait and see.
How is everyone? The quiet from Gene Bio's HQ is deafening.
I'll take a piece of that action. $1.50 on Never.
Lights have on and off switches attached ..you nor anyone else knows anything here.
That would be a helluva turnaround…
JJ24.....I Bet We Get Some Filings Soon.....OTCQB Listing And Trading....I Look Forward To Better Days.....Yes We Will Have That Drink
They are not responding to anyone as far as I know. Clear sign that lights out.
Please let us all know how you know the project is dead ...as you called it. thank you.
Hopefully we get to have those drinks soon Bentley!
Would've been nice to get some new faces taking over. Unfortunately, this project is dead.
Awesome, then somebody else can run the program. Lol!
CRXM??
Most of them looked like old farts (late 60s). Might even be gone with Covid already
Maybe these people at this company will have something to entertain all the people that dropped money into this company by end of 2022????
Let's hope so??
CRXM???
Every time I watch this clip I think of CRXM !!!
Love the "fashionably late"
Someone may be pissed off for modifying their favorite phrase
6 weeks into the near year. CRXM is at the "fashionably late" stage in giving an update on the trial starting.
On August 2, 2021, the Audit Committee approved the appointment of RAM Associates, LLP (“RAM Associates”) as our new independent registered public accounting firm, effective immediately, to perform independent audit services for the fiscal years ending December 31, 2021 and 2020. RAM Associates has served as the auditor for Nostrum Laboratories, Inc. and its affiliates, which are subsidiaries of Nostrum Pharmaceuticals LLC, our largest shareholder, since 2008.
Clinicaltrials.com update:
https://clinicaltrials.gov/ct2/show/NCT02928094?term=generx&rank=1
Understanding refractory angina and the AFFIRM study:
https://www.myrefractoryangina.com/
Taxus Cardium Announces Name Change To Gene Biotherapeutics
January 10, 2018 PR-M01-18-NI-021
SAN DIEGO, Jan. 8, 2018 /PRNewswire/— Taxus Cardium Pharmaceuticals Group (Trading Symbol: CRXM) today announced plans to affect a name change from Taxus Cardium Pharmaceuticals Group Inc. to Gene Biotherapeutics Inc.
The name change reflects the Company's plan to exclusively focus on the late-stage clinical research and commercialization of gene-based biotherapeutics for niche markets in the oncology and cardiology spaces for patients with unmet medical needs. Gene Biotherapeutics is actively pursuing the acquisition of clinical development and commercialization rights to new and innovative, late-stage, DNA-based product opportunities focused on multiple forms of cancer to leverage the company's established and validated adenovector-based technology platform and deep experience in the clinical advancement and commercialization of gene therapy product candidates.
Previously, the Company established Angionetics Inc., an 85% majority-owned subsidiary, to lead Gene Biotherapeutics' cardiovascular clinical research and commercialization activities. Angionetics is currently focused on independent financings to support advancement of the FDA-cleared, Generx AFFIRM Phase 3 clinical study of patients with refractory angina (myocardial ischemia) due to advanced coronary artery disease. There are an estimated 1.0 million patients with refractory angina in the United States. Gene Biotherapeutics' plan to advance forward to establish Angionetics as an independent company remains unchanged. As previously reported, Gene Biotherapeutics expects to retain a substantial long-term equity investment in Angionetics following completion of the planned external financings. For more information about the Generx AFFIRM Phase 3 clinical study visit www.MyRefractoryAngina.com.
Angionetics is also considering the initiation of multiple Phase 2 clinical studies to evaluate the Generx angiogenic gene therapy product candidate as a treatment for patients with Cardiac Syndrome X (microvascular dysfunction) and certain forms of congestive heart failure, including ischemic cardiomyopathy.
Angionetics' Generx [Ad5FGF-4] is a first in class, disease altering, one-time administered, late-stage, angiogenic gene therapy product candidate which has been biologically engineered to enhance blood flow (perfusion) in ischemic regions of the heart by leveraging cardiac plasticity to promote the natural formation and growth of microvascular coronary structures (collateral vessels). This is achieved by stimulating and augmenting the heart's innate natural capacity to modulate the enlargement of pre-existing collateral arterioles (arteriogenesis), and to form new capillary vessels (angiogenesis) in select ischemic regions downstream from large coronary arteries.
Angionetics is being uniquely positioned to become a leading molecular interventional cardiology company, and is seeking to develop a portfolio of new and innovative, single-treatment, gene-based, catheter-administered therapeutic products focused on the biologic modulation of cardiac conductivity, contraction and angiogenic revascularization to address the global unmet medical needs of millions of patients with multiple forms of heart disease. Consistent with Angionetics' business strategy, the company is currently considering the acquisition of several early-stage gene therapy product candidates. To learn more about Angionetics visit www.angionetics.com.
As previously reported, Gene Biotherapeutics further plans to monetize its FDA-cleared, U.S.-patented, Excellagen, a highly-purified, aseptically-manufactured, fibrillar bovine collagen [2.6%] flowable dermal matrix for the treatment of diabetic neuropathic lower extremity ulcers, pressure and venous ulcers as well as other wound healing applications. Excellagen has demonstrated its medical utility as a delivery platform for stem cells, and also carries the potential as a topical dermal delivery vehicle for small molecule drugs, peptides, proteins, and exosomes. Excellagen® has been designated as a skin substitute (bearing a unique product Q Code), in accordance with the standards established by the U.S. Centers for Medicare and Medicaid Services (CMS). For more information about Excellagen, visit https://www.youtube.com/watch?v=D2GYCYc_8JE.
As of December 31, 2017, approximately 14.3 million shares of Gene Biotherapeutics Common Stock were issued and outstanding, and approximately 4.6 million additional shares of Common Stock have been reserved for future issuance upon the conversion of the Series A Convertible Preferred Stock.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |